Patient Experience

Patient Experience

Epik B5

A Phase III, randomized, double-blind, placebo-controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor This study will assess the efficacy of alpelisib plus fulvestrant in participants with Hormone receptor-positive, HER2-negative, advanced breast cancer after treatment with a CDK4/6 inhibitor and an aromatase inhibitor.
Study Phase: Phase 3
Principal Investigator: Dr Grainne O'kane
Further information

Shamrock

Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a cytotoxic chemotherapy-sparing approach to curative-intent treatment
Study Phase: Phase 3
Principal Investigator: Dr Ciara O'Hanlon Brown
Further information

Enquire about a Cancer Clinical Trial

If you would like more information on Cancer Clinical Trials you can contact us.

Make an enquiry